Login
Why Novo Nordisk Stock Popped Monday
Key Points
Novo Nordisk is cutting Ozempic prices again.
It's also partnering with GoodRx to cut prices on Ozempic and Wegovy.
And Novo Nordisk just won approval to use Wegovy to treat liver disease.
Shares of Novo Nordisk (NYSE: NVO), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.
Two of these announcements concern weight loss. One doesn't.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
Novo Nordisk cuts prices
In a pair of press releases this morning, Novo announced it's cutting the cash cost for 0.5 mg, 1 mg, and 2 mg doses of Ozempic to $499 per month "for self-paying patients." And separately, the company says it's collaborating with GoodRx to sell all dose sizes of both Ozempic and Wegovy to patients for the $499 price.
In both instances, Novo appears to be targeting competition from telehealth providers like Ro and Hims & Hers Health, declaring, "We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives [because of price], that's one too many."
On top of all that, CNBC reports that Novo's Wegovy GLP-1 drug has won FDA approval for treatment of metabolic dysfunction-associated steatohepatitis (MASH) liver disease in adults.
Is Novo Nordisk stock a buy?
In a statement, Novo pointed out that Wegovy is now "the first and only GLP-1 treatment approved for MASH," a disease that affects about 5% of U.S. adults, opening up a new market that (for now) neither Hims & Hers nor archrival Eli Lilly can compete in.
Valued at just 13 times trailing earnings, Novo Nordisk stock was already looking cheap based on its 3.5% dividend yield and 11.3% projected long-term earnings growth rate. While it's too soon to say how much the MASH indication will add to that growth rate, it will add something.
That fact alone makes Novo Nordisk stock even more of a buy today.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,106,071!*
Now, it’s worth noting Stock Advisor’s total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of August 18, 2025
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
